Journal article
Indacaterol provides sustained 24 h bronchodilation on once‐daily dosing in asthma: a 7‐day dose‐ranging study
Abstract
BACKGROUND: Indacaterol is a novel, once-daily beta(2)-agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. Studies were required to determine optimal dose(s) for continuing investigation.
OBJECTIVE: A dose-ranging study was undertaken to evaluate efficacy and safety of indacaterol.
Authors
LaForce C; Alexander M; Deckelmann R; Fabbri LM; Aisanov Z; Cameron R; Owen R; Higgins M
Journal
Allergy, Vol. 63, No. 1, pp. 103–111
Publisher
Wiley
Publication Date
January 2008
DOI
10.1111/j.1398-9995.2007.01555.x
ISSN
0001-5148
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, InhalationAdolescentAdultAgedAsthmaDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansIndansMaleMetered Dose InhalersMiddle AgedMultivariate AnalysisProbabilityQuinolonesReference ValuesRespiratory Function TestsSeverity of Illness IndexSpirometryTreatment Outcome